Here are 1-2 brief analogies to describe Codexis (CDXS):

• The Intel Inside for industrial biotech processes. (Analogy: Intel for microprocessors)
  Just as Intel provides the essential processing power for computers, Codexis engineers and supplies the core biological components (enzymes) that drive efficiency and new capabilities in chemical and biopharmaceutical manufacturing for other companies.
• A specialized Thermo Fisher Scientific for engineered enzymes. (Analogy: Thermo Fisher Scientific for broad scientific instruments and reagents)
  While Thermo Fisher supplies a vast array of tools to the scientific community, Codexis is a more focused supplier, specifically engineering and providing advanced enzyme tools and the platform to create them, primarily for pharmaceutical and chemical companies.

• Biocatalyst Products: Enzymes and other proteins that accelerate chemical reactions for industrial applications.
• Intermediate Chemicals: Chemical compounds produced for further processing by other companies.
• Codex Biocatalyst Panels and Kits: Ready-to-use kits enabling customers to screen and optimize chemical processes with biocatalysts.
• Biocatalyst Screening Services: Expert services to identify and develop optimal biocatalysts for specific chemical transformations.
• Protein Engineering Services: Custom services to design and modify proteins for enhanced performance and desired properties.
• CodeEvolver Protein Engineering Technology Platform: A proprietary technology used to develop high-performance biocatalysts and discover novel biotherapeutic drug candidates.
• Biotherapeutic Drug Candidates: Novel protein-based drug candidates discovered using their platform for targeted human diseases.
• Molecular Biology and In Vitro Diagnostic Enzymes: Specialized enzymes designed for use in molecular biology research and diagnostic tests.

Codexis (CDXS) primarily sells its products and services to other companies.

Based on the provided information, its major customers are:

• Pharmaceutical manufacturers

The background description does not specify individual customer company names or their public symbols.

Alison Moore, PhD, President and Chief Executive Officer

Dr. Moore was appointed CEO of Codexis effective November 7, 2025. She brings extensive experience as a biotechnology and pharmaceutical executive, having served as Chief Technical Officer of Allogene Therapeutics, a clinical-stage company. Prior to Allogene, she spent 20 years at Amgen, holding roles such as Senior Vice President, Process Development, and in Supply Chain and Manufacturing. She also has experience at Genentech as a Director in Chemistry, Manufacturing and Controls, and Regulatory Affairs. Her background is centered on perfecting and scaling novel manufacturing platforms.

Georgia Erbez, Chief Financial Officer and Chief Business Officer

Ms. Erbez was appointed CFO of Codexis as of September 30, 2024. She is a seasoned financial and operations executive, most recently serving as Chief Operating Officer at Walking Fish Therapeutics, a private B cell therapy company. Previously, she was the Chief Financial Officer of Harpoon Therapeutics, a public T cell therapy company, and held CFO roles at Zosano Pharma Corp., Revolution Medicines, Asterias Biotherapeutics, and Raptor Pharmaceuticals. Her earlier career includes senior positions in investment banking at Cowen and Company and Jefferies, and she was a Managing Director at Axiom Financial Partners, a life-sciences consulting firm.

Stefan Lutz, PhD, Chief Scientific Officer

Dr. Lutz joined Codexis in 2020 as the Senior Vice President of Research, leading the company's protein discovery team. Before joining Codexis, he was a Professor and Chair of the Chemistry Department at Emory University, a position he held after joining the university in 2002 and ascending to Chair in 2014. He has also consulted for AgriMetis and served on the scientific advisory boards of ZuvaChem, CODA Genomics Inc., and SynBioX Inc.

Britton Jimenez, Senior Vice President, Sales and Marketing

Mr. Jimenez joined Codexis in July 2024, taking responsibility for all commercial activities across RNA manufacturing and pharma biocatalysis. Prior to Codexis, he served as Vice President, Global Partners at Catalent Pharma Solutions. Before Catalent, he was Vice President of Business Development at Mayne Pharma, where he managed commercial activities and drove growth of their CDMO business, ultimately facilitating its $475 million sale in 2022.

Key Business Risks for Codexis (CDXS)

Codexis, Inc. (CDXS) faces several key risks inherent to its operations in the biotechnology sector, particularly concerning its financial stability, the execution of its strategic technological pivot, and its reliance on a concentrated customer base.

The most significant risk to Codexis's business is its **ongoing financial health and profitability challenges**. The company has a history of net losses, with concerning profitability metrics such as negative operating and net margins. Despite some recent quarterly profitability, Codexis continues to burn cash, and its balance sheet strength is rated as poor, largely due to high leverage and a high debt-to-equity ratio. While current financial resources are projected to last through 2027, the sustained inability to achieve and maintain overall profitability poses a fundamental threat to its long-term viability.

Another crucial risk is the **successful execution and commercialization of its strategic shift to the ECO Synthesis platform**. Codexis is heavily investing in this platform, moving from a heritage enzyme supplier to a full-service oligonucleotide Contract Development and Manufacturing Organization (CDMO). The success of this pivot depends on validating the performance of these new technologies at scale, achieving regulatory acceptance, and converting initial feasibility studies into higher-margin, multi-year licensing, clinical supply, and commercial supply agreements. Delays in scaling production to kilogram volumes or a slower-than-anticipated adoption rate could significantly impede future revenues and profitability.

Finally, Codexis faces substantial **customer concentration risk and dependence on collaborations**. A limited number of customers account for a significant portion of its total revenue, with key agreements driving a large share of its product revenue. The loss or reduction of business from one or more of these significant customers, or the termination of development programs by collaborators, could materially and adversely affect Codexis's revenues, financial condition, and results of operations. Additionally, revenue can be volatile due to the unpredictable nature of customer manufacturing schedules and clinical trial progression.

Codexis, Inc. (CDXS) operates in several key addressable markets related to enzymes, proteins, and their applications in various industries, including pharmaceuticals and diagnostics. Based on recent information, the addressable markets for their main products and services are as follows:

• Biocatalyst Market: The global biocatalyst market was valued at approximately USD 607.6 million in 2023 and is projected to reach around USD 925.2 million by 2030. Other estimates place the global market at USD 755.9 million in 2025, expected to grow to USD 1,329.3 million by 2033.
• Protein Engineering Market: The global protein engineering market size was valued at an estimated USD 3.65 billion in 2025 and is projected to grow to USD 14.46 billion by 2034. Another report indicates a global market size of USD 3.5 billion in 2025, growing at a compound annual growth rate (CAGR) of 16.4% from 2026 to 2035.
• In-vitro Diagnostics Enzymes Market: The global in-vitro diagnostics enzymes market was estimated at USD 2.49 billion in 2025 and is predicted to increase to approximately USD 4.34 billion by 2034. Other figures suggest the global market was valued at USD 2.92 billion in 2024 and is expected to reach USD 5.69 billion by 2033.
• RNA/siRNA Manufacturing Technologies: Codexis has identified an estimated total addressable annual market of USD 2 billion for production technologies in the siRNA/RNA therapeutics market within the next five years. This market is global.
• Biologics Drug Discovery Market: The global biologics drug discovery market is projected to expand from a valuation of USD 9.66 billion in 2025 to USD 15.49 billion by 2031.

Expected Drivers of Future Revenue Growth for Codexis (CDXS)

Codexis (CDXS) is anticipated to drive future revenue growth over the next 2-3 years through several key initiatives, primarily centered on its ECOsynthesis platform for RNA manufacturing and the continued performance of its core biocatalysis business.

1. Expansion and Commercialization of the ECOsynthesis RNA Manufacturing Platform: Codexis is strategically focusing on its proprietary ECOsynthesis platform for enzymatic RNA manufacturing, particularly for siRNA therapeutics. The company has a robust sales pipeline with 55 opportunities across 40 individual companies, demonstrating strong industry interest. This platform is seen as a crucial disruptive alternative to traditional chemical synthesis, addressing the increasing demand for siRNA medicines.

2. Growth through Strategic Partnerships and CDMO Agreements: Codexis is actively expanding its network of partners, having already signed three CDMO agreements with companies like Bachem, Nitto Avecia, and Axolabs. These collaborations are vital for the widespread adoption and commercialization of the ECOsynthesis platform. The company is also pursuing additional licensing deals with major pharmaceutical companies, further validating its technology and generating non-dilutive capital.

3. Scaling Up of GMP Manufacturing Capabilities: To meet anticipated demand for its ECOsynthesis platform, Codexis plans to begin retrofitting a new Good Manufacturing Practice (GMP) facility in the second half of 2026, with full operational capability targeted by the end of 2027. This expansion will enable the company to provide large-scale clinical and commercial GMP-grade siRNA material, a critical step for securing larger contracts and serving the growing RNA therapeutics market.

4. Stable Performance and Profitability of Small-Molecule Biocatalysis Business: While the primary focus is on ECOsynthesis, Codexis' traditional small-molecule biocatalysis segment has returned to profitable margins and stable revenue. This established business continues to contribute to the company's overall financial health and provides a steady revenue stream as the newer platforms scale up.

5. Technological Advancements and Innovation in siRNA Manufacturing: Codexis is committed to ongoing innovation within its ECOsynthesis platform, including advancements in stereoisomer control for siRNA manufacturing. Such developments aim to enhance the potency and purity of siRNA products, potentially leading to new applications, expanded market share, and premium offerings that can drive future revenue growth. The company is also scaling up its production capabilities, with plans to reach half a kilogram scale by the end of 2026.

Share Issuance

• Codexis raised $31 million in 2024 through an At-The-Market (ATM) equity facility.
• The company reported proceeds from the issuance of common stock of $19.91 million for the trailing twelve months ending September 2025, $33.35 million in fiscal year 2024, and $9.07 million in fiscal year 2023.

Inbound Investments

• Codexis completed a $37.8 million Technology Transfer Agreement with Merck, with cash expected by the end of 2025, serving as a significant non-dilutive cash injection.
• In February 2024, Codexis secured a loan facility agreement with Innovatus Capital Partners, LLC for up to $40 million, including an upfront payment of $30 million.
• Aberdeen Group plc increased its stake in Codexis Inc. on December 31, 2025, acquiring an additional 3,874,436 shares at $1.63 per share, bringing its total holdings to 7,966,498 shares, representing 8.82% of the company's outstanding shares.

Outbound Investments

• Codexis's most recent investment deal was a Later Stage VC with Molecular Assemblies on September 21, 2022.

Capital Expenditures

• Capital expenditures were -$5.73 million for the trailing twelve months ending September 2025, -$4.31 million in fiscal year 2024, and -$4.42 million in fiscal year 2023.
• The company plans to begin construction of a new GMP (Good Manufacturing Practice) plant in the second half of 2026, which is expected to be fully operational by the end of 2027.
• Savings from an organizational restructuring in late 2025 are intended to partially offset the costs associated with the GMP facility build-out.